Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CX-2029 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| CX-2029 Escalation | EXPERIMENTAL | Dose Escalation and Determination |
| CX-2029 Biomarker | EXPERIMENTAL | Characterization of CX-2029 in the tumor microenvironment in subjects with select tumor types |
| CX-2029 Expansion | EXPERIMENTAL | Evaluate antitumor activity of CX-2029 |
| Name | Type | Description |
|---|---|---|
| CX-2029 | DRUG | CX-2029 Monotherapy |
Inclusion Criteria: 1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable tumors 2. Patients demonstrating disease progression after treatment with approved therapies that are known to confer life-prolonging benefit, or who are intolerant to or have d...
CX-2029 is an investigational small molecule developed by CytomX Therapeutics for the treatment of adult solid tumors. It was studied in a Phase 1 clinical trial that also enrolled patients with diffuse large B cell lymphoma. It is not an approved therapy and remains in clinical development.
CX-2029 was studied in adults with solid tumors, including head and neck cancer, non small cell lung cancer, and esophageal cancer, as well as diffuse large B cell lymphoma. It is an investigational agent and has not been approved for any indication.
CX-2029 targets CD71, a protein also known as the transferrin receptor. CD71 is a cell surface protein, and CX-2029 was designed as a small molecule directed at this target. The Phase 1 PROCLAIM-CX-2029 trial evaluated its safety and activity in solid tumors and DLBCL.
CX-2029 is developed by CytomX Therapeutics, Inc., which trades on the Nasdaq under the ticker CTMX. The company sponsored the Phase 1 PROCLAIM-CX-2029 trial evaluating the agent in solid tumors and diffuse large B cell lymphoma.
CX-2029 is in Phase 1 development. Its single clinical trial, PROCLAIM-CX-2029, has been completed. The drug is investigational and has not been approved by the FDA for any indication.
CX-2029 was evaluated in one clinical trial, NCT03543813, titled PROCLAIM-CX-2029. This completed Phase 1 study enrolled 133 patients with solid tumors or diffuse large B cell lymphoma across the United States, South Korea, Spain, and the United Kingdom. It was a controlled trial without randomization or double blinding.